EMEA committee gives positive opinion about insulin products

Published: 1-Jul-2002


The EMEA's Committee for Proprietary Medicinal Products has given a positive opinion on a range of insulin medicines: Actrapid, Actraphane, Insulatard, Mixtard, Monotard, Protophane, Ultratard and Velosulin. The committee also began risk-benefit reviews of gatifloxacin, (containing Bonoq, Crispin, Urobonoq, Urocrispin and associated product names) and nimesulide containing medicinal products (Aulin, Mesulide, Nimed and associated product names). These studies follow safety and efficacy concerns raised by Belgium and Finland. The committee also began reviews of loratadine and desloratadine containing Clarityn and Azomyr following a safety concern referral by Sweden.

Summaries of the opinions can be found at www.emea.eu.int/htms/human/opinion/opinion.htm

You may also like